BIOTECH ASSISTANT / FIELD NOTES

Eurostars-backed CAPSULIX targets mRNA/LNP manufacturing for engineered T cells

Company / institutional announcement · OZ Biosciences

Source published: 2026-10-14 · Event / reporting date: 2026-10-01

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

The CAPSULIX consortium of OZ Biosciences, ExploRNA, and Miltenyi received Eurostars support for a three-year project with a total budget of €1,518,766. It will combine novel cap-analog mRNA or self-amplifying RNA with biodegradable LNPs for nonviral CAR-T manufacturing. GMP-compatible process development and preclinical validation are objectives. The total project budget is not necessarily the amount of grant funding.

Why it may matter

Nonviral cell engineering links RNA design, delivery, and manufacturing processes; any proposed cost or performance advantages require supporting process and functional data.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

mRNA / LNP Formulation Development & Manufacturing

Related updates

2026-11-06Moderna / ACCESS Newswire

Moderna raises 2026 revenue outlook after third-quarter growth

Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.

mRNA / LNP Ask AI ↗

2026-11-05Ethris / GlobeNewswire

Ethris reports exploratory antiviral and exposure-response signals for nasal ETH47 in asthma

Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.

mRNA / LNP Clinical Pharmacology & Model-Informed Development Ask AI ↗

2026-11-04Moderna / ACCESS Newswire

Moderna reports initial mRNA-2808 T-cell engager results in multiple myeloma

Moderna reported initial Phase 1/2 MyEngage findings for mRNA-2808, which encodes three T-cell engagers. Four confirmed responses occurred among 11 response-evaluable patients. Twelve patients had received treatment; Grade 3 or higher treatment-related adverse events occurred in 41.7%. These small, uncontrolled findings are preliminary and do not establish comparative benefit.

mRNA / LNP Ask AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗